Clindamycin and nicotinic neuromuscular transmission.
Upon clindamycin treatment a patient with Parkinson's disease showed marked tremor improvement which may be explained by clindamycin's ability to inhibit in-vitro nicotinergic, but not muscarinic signal transmission.
Schulze
J
J
Toepfer
M
M
Schroff
K C
KC
Aschhoff
S
S
Remien
J
J
Müller-Felber
W
W
Endres
S
S
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002981:Clindamycin / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D006801:Humans; D051379:Mice; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D011976:Receptors, Muscarinic / Q000187:drug effects*; D011978:Receptors, Nicotinic / Q000187:drug effects*; D015398:Signal Transduction / Q000187:drug effects; D009435:Synaptic Transmission / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D011976:Receptors, Muscarinic; D011978:Receptors, Nicotinic; D002981:Clindamycin